Youli Zu, MD, PhD

Professor of Pathology and Genomic Medicine, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Research Lab


yzu@HoustonMethodist.org
Biography

After obtaining his MD and PhD degrees, Dr. Zu attended the University of Connecticut Health Center as a postdoctoral fellow and later remained there as an assistant professor. He then spent four years in pathology residency training at New York University, followed by a two-year hematopathology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Zu joined the Department of Pathology and Genomic Medicine at Houston Methodist Hospital in 2004, where he currently serves as the Medical Director of the Hematopathology Section. He is also Professor of Pathology and Laboratory Medicine at the Weill Cornell Medical College of Cornell University. In addition to his clinical responsibilities, Dr. Zu is also the Director of the Cancer Pathology research laboratory at the Houston Methodist Research Institute. These combined positions enable him to address clinically-driven questions. As a physician-scientist, Dr. Zu has pioneered the translation of the oligonucleotide aptamers and nanotechnology into clinical applications, and his research is currently funded by multiple NIH and CPRIT grants.

Description of Research

Dr. Zu's clinical interests include diagnosis of hematopoietic and lymphoid disorders. His research centers on the development of novel diagnostics and treatments for these disorders. His laboratory was the first to use aptamer probes to enhance the diagnostic capabilities of multi-color flow cytometry amd immunohistochemical staining, and for rapid detection of circulating tumor cells in whole blood samples. By combining nanotechnology with aptamer technology, Dr. Zu's laboratory is also developing new multi-functional nanomedicine for specific tumor imaging and targeted therapy of several cancer types, including lymphomas, multiple myeloma, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, and hepatocellular (liver) carcinoma. Other directions of his laboratory include studies on the role of cancer stem cells in the development of multiple myeloma and elucidating the molecular mechanisms underlying the myelodysplastic syndrome.

Areas Of Expertise

Aptamer technology Nanomedicine Early cancer detection Targeted cancer therapy
Education & Training

, National Cancer Institute (NCI)
, New York University Medical Center
, University of Connecticut Health Center
, Tsukuba Life Science Research Center, RIKEN
, Kyoto University Graduate School of Medicine
, Jilin Medical College
Publications

B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
Liang, L, Jiang, Y, Chen, JS, Niu, N, Piao, J, Ning, J, Zu, Y, Zhang, J & Liu, J 2016, Human Pathology, vol 57, pp. 1-6. DOI:

Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
Xu-Monette, ZY, Deng, Q, Manyam, GC, Tzankov, A, Li, L, Xia, Y, Wang, XX, Zou, D, Visco, C, Dybkær, K, Li, J, Zhang, L, Liang, H, Montes-Moreno, S, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Wang, SA, Miranda, RN, Piris, MA, Winter, JN, Medeiros, LJ, Li, Y & Young, KH 2016, Clinical Cancer Research, vol 22, no. 14, pp. 3593-3605. DOI:

Aptamers: Versatile molecular recognition probes for cancer detection
Sun, H, Tan, W & Zu, Y 2016, Analyst, vol 141, no. 2, pp. 403-415. DOI:

SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol 11, no. 1, e0147674. DOI:

p63 expression confers significantly better survival outcomes in highrisk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function
Xu-Monette, ZY, Zhang, S, Li, X, Manyam, GC, Wang, XX, Xia, Y, Visco, C, Tzankov, A, Zhang, L, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, HJ, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, JL & Young, KH 2016, Aging, vol 8, no. 2, pp. 345-365.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Ye, Q, Xu-Monette, ZY, Tzankov, A, Deng, L, Wang, X, Manyam, GC, Visco, C, Montes-Moreno, S, Zhang, L, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, Medeiros, LJ, Hu, VDS & Young, KH 2016, Oncotarget, vol 7, no. 3, pp. 2401-2416. DOI:

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Xu-Monette, ZY, Dabaja, BS, Wang, X, Tu, M, Manyam, GC, Tzankov, A, Xia, Y, Zhang, L, Sun, R, Visco, C, Dybkaer, K, Yin, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Zhao, X, Winter, JN, Piris, MA, McDonnell, TJ, Miranda, RN, Li, Y, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 12, pp. 1555-1573. DOI:

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
Liu, Z, Xu-Monette, ZY, Cao, X, Manyam, GC, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, OMalley, DP, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 10, pp. 1297-1314. DOI:

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Zhao, N, Pei, SN, Qi, J, Zeng, Z, Iyer, SP, Lin, P, Tung, CH & Zu, Y 2015, Biomaterials, vol 67, pp. 42-51. DOI:

Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions
Ok, CY, Xu-Monette, ZY, Li, L, Manyam, GC, Montes-Moreno, S, Tzankov, A, Visco, C, Dybkær, K, Routbort, MJ, Zhang, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Rao, H, Møller, MB, Winter, JN, Piris, MA, Wang, SA, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 9, pp. 1202-1213. DOI:

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol 30, no. 4, pp. 987-91. DOI:

CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation
Han, X, Liu, Z, Jo, MC, Zhang, K, Li, Y, Zeng, Z, Li, N, Zu, Y & Qin, L 2015, Science advances, vol 1, no. 7, pp. e1500454. DOI:

A Highlight of recent advances in aptamer technology and its application
Sun, H & Zu, Y 2015, Molecules, vol 20, no. 7, pp. 11959-11980. DOI:

Pre-clinical efficacy of combined therapy with novel ß-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W, Sharma, S, Saha, S, Shah, B, Devaraj, SGT, Sun, B, Horrigan, S, Leveque, C, Zu, Y, Iyer, S & Bhalla, KN 2015, Leukemia, vol 29, no. 6, pp. 1267-1278. DOI:

Aptamers and their applications in nanomedicine
Sun, H & Zu, Y 2015, Small, vol 11, no. 20, pp. 2352-2364. DOI:

Mutated genes and driver pathways involved in myelodysplastic syndromes - a transcriptome sequencing based approach
Liu, L, Wang, H, Wen, J, Tseng, CE, Zu, Y, Chang, CC & Zhou, X 2015, Molecular BioSystems, vol 11, no. 8, pp. 2158-2166. DOI:

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma
Li, L, Xu-Monette, ZY, Ok, CY, Tzankov, A, Manyam, GC, Sun, R, Visco, C, Zhang, M, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Wang, J, Parsons, BM, Winter, JN, Piris, MA, Pham, LV, Jeffrey Medeiros, L & Young, KH 2015, Oncotarget, vol 6, no. 27, pp. 23157-23180. DOI:

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
Chen, J, Xu-Monette, ZY, Deng, L, Shen, Q, Manyam, GC, Martinez-Lopez, A, Zhang, L, Montes-Moreno, S, Visco, C, Tzankov, A, Yin, L, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Han van Krieken, J, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Farnen, JP, Winter, JN, Piris, MA, Pham, L & Young, KH 2015, Oncotarget, vol 6, no. 8, pp. 5597-5614.

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?
Ok, CY, Ye, Q, Li, L, Manyam, GC, Deng, L, Goswami, RR, Wang, X, Montes-Moreno, S, Visco, C, Tzankov, A, Dybkaer, K, Zhang, L, Abramson, J, Sohani, AR, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Zhang, S, Parsons, BM, Xu, M, Møller, MB, Winter, JN, Piris, MA, Xu-Monette, ZY, Medeiros, LJ & Young, KH 2015, Oncotarget, vol 6, no. 16, pp. 13933-13945. DOI:

Erratum to Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries [Oncotarget, 8, (2015), 5615-5633]
Xu-Monette, ZY, Tu, M, Jabbar, KJ, Cao, X, Tzankov, A, Visco, C, Nagarajan, L, Cai, Q, Montes-Moreno, S, An, Y, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Farnen, JP, Winter, JN, Piris, MA, Miranda, RN, Medeiros, LJ & Young, KH 2015, Oncotarget, vol 6, no. 16, pp. 14720.